Kinins and their B1 and B2 receptors as potential therapeutic targets for pain relief.

Abstract

Kinins are endogenous peptides that belong to the kallikrein-kinin system, which has been extensively studied for over a century. Their essential role in multiple physiological and pathological processes is demonstrated by activating two transmembrane G-protein-coupled receptors, the kinin B1 and B2 receptors. The attention is mainly given to the pathological role of kinins in pain transduction mechanisms. In the past years, a wide range of preclinical studies has amounted to the literature reinforcing the need for an updated review about the participation of kinins and their receptors in pain disorders. Here, we performed an extensive literature search since 2004, describing the historical progress and the current understanding of the kinin receptors' participation and its potential therapeutic in several acute and chronic painful conditions. These include inflammatory (mainly arthritis), neuropathic (caused by different aetiologies, such as cancer, multiple sclerosis, antineoplastic toxicity and diabetes) and nociplastic (mainly fibromyalgia) pain. Moreover, we highlighted the pharmacological actions and possible clinical applications of the kinin B1 and B2 receptor antagonists, kallikrein inhibitors or kallikrein-kinin system signalling pathways-target molecules in these different painful conditions. Notably, recent findings sought to elucidate mechanisms for guiding new and better drug design targeting kinin B1 and B2 receptors to treat a disease diversity. Since the kinin B2 receptor antagonist, Icatibant, is clinically used and well-tolerated by patients with hereditary angioedema gives us hope kinin receptors antagonists could be more robustly tested for a possible clinical application in the treatment of pathological pains, which present limited pharmacology management.

• Authors: Indiara Brusco, Maria Fernanda Pessano Fialho, Gabriela Becker, Evelyne Silva Brum, Amanda Favarin, Lara Panazzolo Marquezin, Patrick Tuzi Serafini, Sara Marchesan Oliveira
• Journal: Life sciences (Life Sci) Vol. 314 Pg. 121302 (Feb 01 2023) ISSN: 1879-0631 [Electronic] Netherlands
• PMID: 36535404 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Receptor, Bradykinin B2
• Receptor, Bradykinin B1
• Peptides

Topics

• Humans
• Receptor, Bradykinin B2
• Pain (drug therapy)
• Receptor, Bradykinin B1
• Peptides
• Fibromyalgia